CAR-T Strategy In 2026: Scaling Autologous, Advancing Allogeneic

As clinical experience deepens and commercial adoption accelerates, the CAR-T landscape is entering a new phase of strategic recalibration. Autologous therapies are moving beyond initial indications, while allogeneic platforms continue to mature, prompting organizations to rethink where innovation and investment will deliver the greatest impact. A cross-section of leaders from across the cell therapy ecosystem brings clarity to the scientific advances, manufacturing realities, and market forces shaping this evolution. Key considerations around scalability, accessibility, and long-term efficacy are examined alongside the operational complexities of bringing next-generation therapies to patients.

Gain a clearer view of how priorities are shifting and what it means for development, partnerships, and competitive positioning in 2026 and beyond.